ProShare Advisors LLC Has $173.98 Million Stake in Cardinal Health, Inc. $CAH

ProShare Advisors LLC cut its holdings in shares of Cardinal Health, Inc. (NYSE:CAH) by 9.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,108,450 shares of the company’s stock after selling 120,405 shares during the quarter. ProShare Advisors LLC’s holdings in Cardinal Health were worth $173,982,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in shares of Cardinal Health by 3.3% in the second quarter. Geode Capital Management LLC now owns 6,389,049 shares of the company’s stock valued at $1,069,005,000 after purchasing an additional 205,539 shares during the last quarter. Norges Bank acquired a new stake in shares of Cardinal Health during the 2nd quarter worth about $584,420,000. Invesco Ltd. boosted its holdings in shares of Cardinal Health by 7.3% during the 2nd quarter. Invesco Ltd. now owns 3,037,782 shares of the company’s stock worth $510,347,000 after buying an additional 207,750 shares during the period. Legal & General Group Plc grew its stake in Cardinal Health by 2.0% in the 2nd quarter. Legal & General Group Plc now owns 2,349,767 shares of the company’s stock valued at $394,761,000 after buying an additional 45,812 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in Cardinal Health by 19.1% in the 2nd quarter. Marshall Wace LLP now owns 1,930,967 shares of the company’s stock valued at $324,402,000 after buying an additional 309,335 shares during the last quarter. Institutional investors own 87.17% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Leerink Partners raised their price objective on shares of Cardinal Health from $240.00 to $268.00 and gave the stock an “outperform” rating in a research report on Thursday. Wells Fargo & Company boosted their price target on Cardinal Health from $221.00 to $237.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. Mizuho upped their price objective on Cardinal Health from $222.00 to $235.00 and gave the company an “outperform” rating in a report on Friday. Morgan Stanley set a $255.00 target price on Cardinal Health in a report on Friday. Finally, Wall Street Zen raised shares of Cardinal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Fifteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $241.27.

Cardinal Health Stock Performance

NYSE:CAH opened at $226.85 on Monday. The company has a market cap of $53.38 billion, a price-to-earnings ratio of 32.64, a PEG ratio of 1.48 and a beta of 0.64. Cardinal Health, Inc. has a fifty-two week low of $120.72 and a fifty-two week high of $230.81. The stock has a fifty day moving average price of $206.92 and a 200-day moving average price of $180.29.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.32. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The business had revenue of $65.63 billion during the quarter, compared to analysts’ expectations of $64.88 billion. During the same quarter in the prior year, the business posted $1.93 earnings per share. Cardinal Health’s revenue was up 18.8% compared to the same quarter last year. Research analysts predict that Cardinal Health, Inc. will post 7.95 EPS for the current fiscal year.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.